FDA warns acid reflux therapies may raise C. difficile risk

FDA warns acid reflux therapies may raise C. difficile risk

The FDA has issued a warning stating that proton pump inhibitor therapies may increase risk of diarrhea associated with Clostridium difficile. The warning supports previous research presented at an American College of Gastroenterology meeting in 2010. Many cases of the complication occurred in patients who had other conditions or were taking antibiotics, but PPIs could not be excluded as a possible contributing factor to the infection. MedPage Today (free registration) (2/8)

Full Story